Schizophrenia: Mechanism of action of current and novel treatments

Journal of Clinical Psychiatry

Volumn 75, Issue 4, 2014, Pages 347-348

  Correll, Christoph U ^a,b,c   Kane, John M ^a,b,d  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^c Northwell Health   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT;

BINDING AFFINITY; DRUG ADSORPTION; DRUG BINDING; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG TARGETING; HUMAN; NOTE; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANTIPSYCHOTIC AGENTS; HUMANS; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA;

EID: 84899707460     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.13078co8c     Document Type: Note

References (7)

1. Correll CU. Eta Psychiatry 2010;25(suppl 2):512-521.
2. Inoue A, Nakata Y. JpnJPharmacol. 2001;86(4):376-380.
3. Sesack SR, Carr DB. Physiol Behav. 2002;77(4-5):513-517.
4. Kapur S, Zipursky R, Jones C, et al. Ant I Psychiatry. 2000;157(4):514-520.
5. Krystal JH, Karper LP, Seibyl JP, et al. Arch Gen Psychiatry 1994;51(3):199-214.
6. Kantrowitz JT, Javitt DC. Brain Res Bull. 2010;83(3-4):108-121.
7. Snyder MA, Gao WJ. Front Cell Neurosci. 2013;7:31.